Whether process development, new technologies, or studies and therapies for genetic diseases, autoimmune disorders, and cancer: 22 projects from 13 cities are being supported with €9.5 million through the SPARK-BIH project funding program at the Berlin Institute of Health at Charité (BIH), as part…
With the establishment of an ARC Innovation Center, Charité – Universitätsmedizin Berlin and the Berlin Institute of Health at Charité (BIH) are creating a new organizational framework to advance medical innovations rapidly and in a targeted manner. ARC stands for Accelerate, Redesign, Collaborate.…
The new software tool ovrlpy improves quality control in spatial transcriptomics, a key technology in biomedical research. Developed by the Berlin Institute of Health at Charité (BIH) in international collaboration, ovrlpy is the first tool to identify cell overlaps and folds in tissue sections,…
The Berlin Institute of Health at Charité (BIH) is strengthening its research faculty in February with the appointments of Dr. Leif Si-Hun Ludwig and Dr. Daniel Ortmann. Ludwig has been awarded a prestigious Heisenberg professorship in stem cell dynamics and mitochondrial genomics, a position funded…
SPARK-BIH celebrated its 10th anniversary this fall with a three-day series of events at the historic Villa Elisabeth in Berlin. The occasion brought together more than 220 participants — including colleagues, founders, supporters, advisors, alumni, and current SPARK teams — to reflect on a decade…
A person's metabolism is as unique as their fingerprint, and so is their risk of developing certain diseases. A better understanding of the genetic influences on metabolism could open up new therapeutic options. Researchers at the Berlin Institute of Health at Charité (BIH) and Queen Mary University…
The Berlin Institute of Health at Charité (BIH) is coordinating the central European research project "EU-CiP" (European Cancer Information Portal). This project is funded with 12 million euros over four years by the European Union's Horizon Europe program. For the first time, it establishes a…
The Berlin Institute of Health at Charité (BIH) and ProBioGen today announced a major collaboration to manufacture materials for gene and cell therapies. The partnership was unveiled at the groundbreaking ceremony for the Berlin Center for Gene and Cell Therapies (BC GCT), which features a 4,600 m²…
An international research team bringing together Prof. Kirsten Kübler from the Berlin Institute of Health at Charité (BIH), and colleagues from Broad Institute of MIT and Harvard, Mass General Brigham and Dana-Farber Cancer Institute has identified a previously unknown mechanism by which the breast…
